SCHEMBL304827

SCHEMBL304827

[CH2]CC(CC)CCCC(CC)CCC

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 4/20 0.39
TSHR P16473 3/20 0.39
CA2 P00918 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43145 0.89
SCHEMBL21815138 0.89
SCHEMBL11254695 0.86 ALDH1A1 (0.48) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL99803 0.84
SCHEMBL199484 0.82 ALDH1A1 (0.42) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL100729 0.82 ALDH1A1 (0.48) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL9394015 0.81 ALDH1A1 (0.33) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL9058676 0.81 ALDH1A1 (0.33) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL23577086 0.80 LMNA (0.52) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL200853 0.80 LMNA (0.52) ALDH1A1TDP1CYP3A4TSHRCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117716006-A Lubricating base oil and polyether compound 捷恩智株式会社 2024-03-15 CN disclosed
EP-4259731-A2 BIO-BASED COALESCING SOLVENTS Battelle Memorial Institute (US) 2023-10-18 EP disclosed
WO-2023166971-A1 POLYIMIDE RESIN COMPOSITION AND MOLDED BODY 三菱瓦斯化学株式会社 2023-09-07 WO disclosed
CN-112351778-B Fused tricyclic heterocycles and therapeutic uses thereof 江苏恒瑞医药股份有限公司 2023-04-04 CN disclosed
WO-2022132820-A2 BIO-BASED COALESCING SOLVENTS BATTELLE MEMORIAL INSTITUTE (US) 2022-06-23 WO disclosed
CN-108495850-B Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2021-11-26 CN disclosed
US-10551345-B2 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2020-02-04 US disclosed
CN-110691775-A Aldehyde pyridine derivative with FGFR4 inhibitory activity, and preparation method and application thereof 上海和誉生物医药科技有限公司 2020-01-14 CN disclosed
EP-2496615-B1 ENVIRONMENTALLY FRIENDLY COLORANT COMPOSITIONS AND LATEX PAINTS/COATINGS MOORE BENJAMIN & CO (US) 2019-09-18 EP disclosed
US-20170356877-A1 POLY AND COPOLY(N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLIED BIOSYSTEMS, LLC (US) 2017-12-14 US disclosed
WO-2005035500-A2 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2005-04-21 WO disclosed
US-6864261-B2 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2005-03-08 US disclosed
WO-2005019353-A2 COPOLYMER SURFACTANTS COLUMBIA INSURANCE COMPANY (US) 2005-03-03 WO disclosed
US-20050039635-A1 Copolymer surfactants BENJAMIN MOORE & CO. 2005-02-24 US disclosed
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides APPLIED BIOSYSTEMS, LLC 2005-02-03 US disclosed
WO-2004104054-A1 POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLERA CORPORATION (US) 2004-12-02 WO disclosed
US-20040127501-A1 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2004-07-01 US disclosed
WO-2004029044-A1 PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS EURO-CELTIQUE, S.A. (LU) 2004-04-08 WO disclosed
US-20040053914-A1 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. 2004-03-18 US disclosed
WO-2003093236-A1 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR EURO-CELTIQUE, S.A. (LU) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053914-A1 Therapeutic agents useful for treating pain SMN1; SMN2, OPRM1, PSEN1 ALDH1A1 416/4885TDP1 997/4885CYP3A4 4358/4885
US-20040127501-A1 Therapeutic agents useful for treating pain CACNA1A, GRIN2A, HTT ALDH1A1 516/4885TDP1 690/4885CYP3A4 3931/4885
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides POLI, PCNA, POLL ALDH1A1 3357/4885TDP1 337/4885CYP3A4 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.